Judiciary Committee Member Chuck Grassley (R-Iowa), pushed Federal Trade Commission (FTC) and Justice Department senior leadership to do more to promote competition and fairness in the agriculture and prescription drug industries during an oversight hearing on antitrust enforcement.
“For quite some time, I’ve been concerned about consolidation and anti-competitive behavior in several areas of the U.S economy, from agriculture, to health care, to technology. While big isn’t necessarily bad, big can facilitate a company’s ability to unfairly exert its market power. Further, large size and industry concentration can intensify a company’s predatory actions and adverse impacts on market participants and consumers,” Grassley said at the hearing.
Featured News
Turkey Widens Hazelnut Price-Fixing Probe to Ferrero, Six Other Companies
Nov 8, 2026 by
CPI
Medtronic Sued Over Alleged Monopoly in Surgical Stapler Market
Nov 8, 2026 by
CPI
Intesa Faces More Branch Sales to Secure Italy’s Approval for MPS Deal
Nov 8, 2026 by
CPI
DOJ Closes Antitrust Investigation as Fox Completes $22 Billion Roku Acquisition
Nov 8, 2026 by
CPI
NCAA Wins Federal Appeals Court Ruling on Five-Year Eligibility
Nov 8, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI